Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma

Table 1 Clinical data of 13 hepatocellular carcinoma (HCC) patients

	Male/Female	Age (yr)	HBV history	HCC stage	HBV viral load (copies DNA/mL)	ALT (U/L)	AFP (μg/L)	TP (g/L)
1	M	32	10	Advanced	< 104	34	> 800	5 6
2	M	50	20	Advanced	5.02 × 106	40	31.9	65
3	F	52	12	Early	3.07 × 106	28	21.4	66
4	M	50	18	Advanced	1.69 × 105	150	60.6	6 3
5	M	49	15	Advanced	3.48 × 105	50	> 1000	7 1
6	M	49	26	Advanced	2.02 × 106	35	121.9	7 3
7	M	45	10	Advanced	2.55 × 106	31	897.9	73
8	M	49	12	Advanced	3.44 × 105	98	< 20	5 8
9	M	49	14	Advanced	1.66 × 105	78	139.6	8 4
1 0	M	51	15	Advanced	1.77 × 106	68	950	6 7
1 1	M	50	12	Advanced	< 104	37	> 1000	5 6
1 2	M	30	8	Early	1.26 × 107	50	> 1210	6 8
1 3	M	53	14	Advanced	9.63 × 105	66	785.2	6 0